Everest Medicines Signed a MoU with Shanghai Pharma Subsidiary to Advance the Commercialization of Xerava (eravacycline) in Mainland China
- Both companies will work closely to promote the import and channel distribution of Xerava in China. SPH Kyuan's experience in drug import and channel distribution will advance the delivery of Xerava to patients
- Xerava was approved in China for cIAI in adult patients & was recommended by multiple treatment guidelines in China and globally. Xerava is expected to be commercially available in mainland China in the Q3’23
- The P-III clinical study of EVER206 is expected to initiate in H2’23. Everest is also working on other important innovative treatment options for infectious diseases incl. taniborbactam for which the company plans to file NDA in China in 2023 for complicated urinary tract inf.
Ref: PRNewswire | Image: Everest medicines
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.